Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease

European Heart Journal

Volumn 26, Issue 17, 2005, Pages 1765-1773

  Wannamethee, S Goya ^a   Lowe, Gordon D O ^b   Shaper, A Gerald ^a   Rumley, Ann ^b   Lennon, Lucy ^a   Whincup, Peter H ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cigarette smoking; Haemostasis; Inflammation; Pipe cigar; Smoking cessation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; WARFARIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; GENERAL PRACTICE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SMOKING CESSATION;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FIBRINOGEN; HEMOSTASIS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 24044554584     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi183     Document Type: Article

References (53)

1. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke. A statement for healthcare professionals from the American Heart Association. Circulation 1997;96:3243-3247.
2. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976;2:1525-1536.
3. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995;274:155-160.
4. Iribarren C, Tekewa IS, Sydney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease and cancer in men. N Engl J Med 1999;340:1773-1780.
5. Shaper AG, Wannamethee SG, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all cause mortality in middle-aged British men. Int J Epidemiol 2003;32:802-808.
6. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987;2:986-988.
7. Scheffler E, Wiest E, Woehrle J, Otto I, Schulz I, Huber L, Ziegler R, Dresel HA. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest 1992;70:263-268.
8. Barua RS, Ambrose JA, Saha DC, Eales Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002;106:905-908.
9. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 1998;141:133-139.
10. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
11. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
12. Yarnell JWG, Sweetnam PM, Rogers S, Elwood PC, Bainton D, Baker IA, Eastham R, O'Brien JR, Etherington MD. Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Path 1987;40:909-913.
13. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifestime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-2176.
14. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-1590.
15. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-1022.
16. Yarnell JWG, Sweetnam PM, Rumley A, Lowe GDO. Lifestyle and hemostatic risk factors for ischaemic heart disease. Arterioscler Thromb Vasc Biol 2000;20:271-279.
17. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker P. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002;89:1117-1119.
18. Bazzano LA, He Jiang, Muntner P, Vupputuri S, Whelton P. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138:891-897.
19. Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Eur Heart J 2003;24:1365-1372.
20. Smith MR, Kinmonth AL, Luben RN, Bingham S, Day NE, Wareham NJ, Welch A, Khaw KT. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 2003;169:331-337.
21. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998;279:1477-1482.
22. Lowe GDO, Yarnell JWG, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell Study. Arteriosder Thromb Vasc Biol 2001;21:603-610.
23. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2004;25:252-259.
24. Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate; meta-analysis of prospective studies of coronary heart disease. Eur Heart J 2000;21:512-520.
25. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol 1999;105:110-116.
26. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981;283:179-186.
27. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetes with and without coronary heart disease. Diabetologia 2004;47:1557-1565.
28. Lowe GDO, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000;84:553-558.
29. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from non-smokers. Am J Public Health 1987;77:1435-1438.
30. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-1790.
31. Whincup PH, Bruce NG, Cook DG, Shaper AG. The Dinamap 1846SX automated blood pressure recorder: comparison with the Hawksley random zero sphygmomanometer under field conditions. J Epidemiol Community Health 1992;46:164-169.
32. Bruce NG, Cook DG, Shaper AG. Differences between observers in blood pressure measurement with an automatic oscillometric recorder. J Hypertens Suppl 1990;4:S11-S13.
33. Siedel J, Hagele EO, Ziegenhorn J, Wahlefield AW. Reagent for the enzymatic determination of serum total with improved lipolytic efficiency. Clin Chem 1983;29:1075-1080.
34. Sugishi H, Uji Y, Okabe H, Uekema K, Kjayuhas N. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol modified enzymes and sulphated alpha cyclodextrin. Clin Chem 1995;41:717-723.
35. Conlon MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70: 380-385.
36. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997;97:785-797.
37. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549-553.
38. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987;113:1006-1010.
39. Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci 2001;100:459-465.
40. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 1995;88:485-489.
41. Lowe GDO. Why do smokers have higher plasma fibrinogen levels than non-smokers? Clin Sci 2001;101:209-210.
42. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104:246-257.
43. Simpson AJ, Gray RS, Moore NR, Booth NA. The effects of smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol 1997;97:208-213.
44. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-1415.
45. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. t-PA-PAI-1 complex as a risk factor for the development of a first stroke. Stroke 2000;31:26-32.
46. Killewich LA, Gardner AW, Macko RF, Hanna DJ, Goldberg AP, Cox DK, Flinn WR. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 1998;27:645-650.
47. Yarnell JWG, Sweetnam PM, Rumley A, Lowe GDO. Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis 2001;12:721-728.
48. c, factor VIIIc and von Willebrand factor and their relations to cardiovascular disease risk factors. Am J Epidemiol 1989;130:925-934.
49. Yarnell JWG. Smoking and cardiovascular disease. Q J Med 1996;89:493-498.
50. Dobson AJ, Alexander HM, Heller RF, Lloyd DM. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol 1991;44:1247-1253.
51. Negri E, La Vecchia C, D'Avanzo B, Nobilli A, La Malfa RG on behalf of the GISSI-EFRIM investigators. Acute myocardial infarction: association with time since stopping smoking in Italy. J Clin Epidemiol Community Health 1994;48:129-133.
52. US Department of Health and Human Services. The health benefits of smoking cessation. A report of the Surgeon General, 1990. Rockville, MD: Centers for Disease Control, Office on Smoking and Health 1990. DHHS Publication No (CDC) 90-8416.
53. Turner JA, McNichol MW, Sillett RW. Distribution of carboxyhaemoglobin concentrations in smokers and non smokers. Thorax 1986;41:25-27.